Aylin Akifova

Junior doctor and researcher currently focused on kidney transplants @ChariteBerlin

[Aylin Akifova @aylinink1]

Excited to share our results from the first RCT on dd-cfDNA after KTx! dd-cfDNA-guided intervention significantly reduced time to AMR-diagnosis compared to clinician-guided biopsy in dnDSA+KTR.
Big thanks to all that contributed to this daring project!🏅Now online on @NDTsocial

[NDT @NDTsocial]

Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation

https://t.co/Ihj59qVsjF

Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and expedite therapy initiation

[Nephrology Times @Neph_Times]

🔗 https://t.co/RPPBzITXH9
In a recent interview, Dr. Aylin Akifova discusses a post hoc analysis showing felzartamab's efficacy in late AMR regardless of prior history of rejection or desensitization. #kidneytransplantation #antibodymediatedrejection #nephrology

[TransplantDirect @TXPDirect]

3 kidney transplants between identical twins performed with no immunosuppression
✅ Up to 22 years follow-up
✅ Excellent graft function
✅ No rejection episodes
Supports immunosuppression-free transplant as a safe, effective option in monozygotic twins. https://t.co/qKEF1zrGvc

[Aylin Akifova @aylinink1]

Long-term transplant success with zero immunosuppression in monozygotic HLAi-twins: Find this new read from out team on @TXPDirect
Believing in the Nobel Prize: Long-term Success After... : Transplantation Direct https://t.co/yTxknww1RB

[Aylin Akifova @aylinink1]

Just online: our latest review now on @TransplantJrnl!

Happy holidays and a successful new year to all peers in transplantation! 💫⬇️

World Transplant Congress 2025 Highlights: Immunosuppression : Transplantation https://t.co/UxygQZxdS8

[Hugh Kearns @ithinkwellHugh]

#Halloween2025
Really scary.

[Aylin Akifova @aylinink1]

Also big congratulations to our dear colleague @ninagoerlich, who also received an award for her innovative research projects on urine microbioma and its impact on infections and immune regulation after kidney transplantation! Very proud to push the field forward @ChariteBerlin!

[Aylin Akifova @aylinink1]

I’m honored to receive the Young Investigator Award 2025 from the German Transplantation Society! My heartfelt thanks to the whole kidney transplant team at Charité, to our patients and all our genuine supporters for your trust and dedication that make this possible! 😌🏆

[Gunnar Henrik Heine @gunnar_heine]

3. Stage #TourAcadémique 24
@MarkusAtHome
Diagnosis of Allograft Rejection Today & Tomorrow
https://t.co/IKHBtwN5l9 via @YouTube

[Aylin Akifova @aylinink1]

Among the ESOT 2025 highlights: Gregor Bond‘s talk on biomarkers to guide the personalisation of the management of organ recipients! State of the art & future to do’s to move the field forward! Results from the recently completed TTV-Guide RCT project loading soon! #ttvguide 🧬

[Aylin Akifova @aylinink1]

Very important work and unique analyis providing granular insights into the molecular effects of felzartamab in antibody-mediated rejection! Congrats @MatthiasDiebold, @schrezenmeier
and everyone involved in this project!

[Matthias Diebold @MatthiasDiebold]

Super happy and proud to present our latest analysis of the CD38 antibody felzartamab in patients with antibody-mediated rejection, published today!

https://t.co/If5RSd6cWw

[TransplantDirect @TXPDirect]

Study highlights the value of donor-derived cell-free DNA (dd-cfDNA) beyond rejection in kidney transplants! dd-cfDNA strongly correlates with microvascular inflammation (MVI)—even without classic rejection markers. @aylinink1 @ChariteBerlin #TXPforAll https://t.co/LS16BvB0lX

[Aylin Akifova @aylinink1]

Hot off the press! 🗞️ We are happy to share some very important critical thoughts around dd-cfDNA testing in kidney transplantation wrapped up in a point & counterpoint paper as part of „Controversies in nephrology“ now published in @Kidney_Int! 🐣🍀

https://t.co/6P1wkP7WLb

[Aylin Akifova @aylinink1]

Check out our latest paper from @ChariteBerlin that provides insights into the dynamics of absolute and relative dd-cfDNA measured by droplet digital PCR in diverse kidney allograft pathologies! Now online on @TXPDirect! https://t.co/0MuACQ2hve

[Aylin Akifova @aylinink1]

together with @ninagoerlich, @schrezenmeier, @WeiMarlene and many others!

[Aylin Akifova @aylinink1]

Todays highlight: 1st Joint Symposium between nephrology @ChariteBerlin and @MayoClinicNeph happening in Berlin! Happy to pave the way towards better kidney health with our peers from @MayoClinic! ☺️

[Neil Renic @NC_Renic]

The two worst feelings in academia are writing and not writing

[Brendon Neuen @brendonneuen]

Rationale and Design of the RENAL LIFECYCLE Trial Assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease

~1500 patients (GFR<25, dialysis, or transplant GFR<45)
PEP: HHF or all-cause mortality (dialysis) and ESKD

https://t.co/nxNCk5YH2w

[MedUni Wien @MedUni_Wien]

Neuer #Antikörper 🔜 Erste wirksame Therapie für einen Transplantatverlust nach einer #Nierentransplantation?

#ResearcheroftheMonth Katharina Mayer von der #MedUniWien hat sich mit der antikörpervermittelten Abstoßungsreaktion befasst. ➡️ https://t.co/h63oFnAKCO

[Aylin Akifova @aylinink1]

Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system - American Journal of Transplantation https://t.co/wR9RKkxtOq

[Aylin Akifova @aylinink1]

@ninagoerlich @schrezenmeier @NDTsocial Thank you, Nina! Hope to see you very soon in Berlin!! 🤗

[Aylin Akifova @aylinink1]

Excited to share our results from the first RCT on dd-cfDNA after KTx! dd-cfDNA-guided intervention significantly reduced time to AMR-diagnosis compared to clinician-guided biopsy in dnDSA+KTR.
Big thanks to all that contributed to this daring project!🏅Now online on @NDTsocial

[NDT @NDTsocial]

Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation

https://t.co/Ihj59qVsjF

Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and expedite therapy initiation